Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Diagnostic
- Drugs
- Disease
- Pharmaceuticals
- Diagnostic Substances
- Medical
- Cancer
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5272
License Grant
The Company intends to enter into royalty agreements with leading manufacturers and distributors for its products, diagnostic kits. The Company's diagnostic kits are commercialization of non-invasive, in vitro diagnostic kits for use in the early detection and prevention of stress-related and neuroscience-based diseases. The kits are designed for use by physicians during routine examinations as a screening device for determining at-risk patients and as a follow-up after initial drug therapy. The kits require only a finger-prick blood sample to identify abnormal blood readings that were previously undetectable.
IPSCIO Record ID: 374859
License Grant
The Parties collaborate in the evaluation, continued development, validation, and use of Licensor’s platform designed for the early detection and diagnosis of diseases and conditions and for quality control and monitoring purposes, in conjunction with the Licensee’s systems and Licensor grants to the Licensee a worldwide exclusive license to sell such products in the Licensee’s point-of-care network of hospitals, clinics and institutions for quality control and monitoring of manufacturing and processing of autologous immune cells manipulated by cell and gene therapies.
License Property
The platform identifies multiple diseases and may be used to track treatment effectiveness, including immunotherapy. Disease intrusion and cell malformation, including cancer, are first detected in the body by the immune system, which is energized to rid the body of the malignancy. The initial immune response is intricate, deploying different metabolic pathways and subtypes of cells. The platform technology is designed to detect and interpret these differential metabolic responses.
Patented ImmunoBiopsyâ„¢ immunometabolism platform with a goal of (I) developing and validating diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Licensee in manufacturing and processing of its cell and gene therapies; (ii) developing new assays to enhance the potency of cell and gene therapies for use within its point-of-care (POCare) platform; and (iii) developing companion diagnostics for potential enhanced patient targeting of cell and gene therapies.
Field of Use
ImmunoBiopsy platform non-invasively measures the metabolic state of the immune system and acts as a diagnostic link to early diseases.
ImmunoBiopsy platform has shown promise in early detection of cancer. The Parties look forward to leveraging this technology in a number of key areas within our POCare platform.
Licensee will use ImmunoBiopsy to help develop and validate diagnostic kits and create new assays to strengthen the potency of cell and gene therapies. Licensee will also develop companion diagnostics to identify those patients most likely to respond to appropriate therapies.
IPSCIO Record ID: 2481
License Grant
The parties have agreed to enter into a collaborative relationship whereby they will jointly develop and commercialize a diagnostic kit for screening and monitoring FGFR (fibroblast growth-factor) mutations in mutant FGFR-associated diseases such as cancer. With effect from the successful completion of the Feasibility kit development, Licensor hereby grants to licensee, under the terms of this agreement, a worldwide exclusive license to test, use, promote, distribute and sell products based on the Pronto (trademarked) technology in the field of screening and detection of mutations in FGFR3. Both parties to transaction are Israel companies.
Field of Use
The rights to certain therapeutic agents which may be utilized in the treatment cancers.
IPSCIO Record ID: 5271
License Grant
The Canadian University sells, transfers and gives to the Canadian Company the technology's intellectual property and all rights, titles and interests including the rights in patent applying on appeal, copyrights, trading secrets, trademarks and any information, confidential or not, about the works and the results in relation with its development.
License Property
The intellectual property relates to diagnostic kit technology platform using a
series of therapeutic molecules, developed kits that could aid in increasing the
health and well-being of individuals suffering from stress-related and
neuroscience-based diseases.
The technology is the neuro-endocrino-immunilogical system diagnosis which technology brought and can bring the development of diagnostic kits which aim to evaluate specifically and directly in blood and biological tissues, the stress mechanism, the sympathetic nervous system and the human hypothalamo-hypophyso-suprarenal axis response.
Field of Use
This agreement pertains in the bio-medical field in relation with neuro-endocrino-immunilogical system diagnosis which technology brought and can bring the development of diagnostic kits which aim to evaluate specifically and directly in blood and biological tissues, the stress mechanism, the sympathetic nervous system and the human hypothalamo-hypophyso-suprarenal axis response in the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
